---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-058512"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-08-24T11:00:37+00:00"
generated_at: "2026-08-24T11:05:43.615280+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences doses first patient in Phase 1/2 FUNCTION-DMD gene editing trial

## Summary
- First patient dosed with PBGENE-DMD, first clinical gene-editing program for DMD, at Arkansas Children's Hospital.
- PBGENE-DMD excises exons 45-55 to restore near full-length dystrophin; applicable to up to 60% of DMD patients.
- Trial enrolling ambulatory DMD patients aged 2-7 with mutations between exons 45-55; initial safety data expected by year-end 2026.
- PBGENE-DMD is wholly owned in vivo program using ARCUS platform; aims to durably improve function.

## SEC filing metadata
- accession: 0001628280-26-058512
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-08-24T11:00:37+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/0001628280-26-058512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-058512
- JSON: https://secwatch.observer/filing/0001628280-26-058512.json
- Plain text: https://secwatch.observer/filing/0001628280-26-058512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.